Alnylam Pharmaceuticals Inc (ALNY)vsGyre Therapeutics Inc. (GYRE)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
GYRE
Gyre Therapeutics Inc.
$7.18
+3.46%
HEALTHCARE · Cap: $647.36M
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 3086% more annual revenue ($3.71B vs $116.59M). ALNY leads profitability with a 8.5% profit margin vs 4.3%. ALNY trades at a lower P/E of 131.7x. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALNY
Hold49
out of 100
Grade: D+
GYRE
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Margin of Safety
-735.1%
Fair Value
$0.94
Current Price
$7.18
$6.24 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Revenue surging 33.4% year-over-year
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
1.7% earnings growth
Smaller company, higher risk/reward
4.3% margin — thin
Operating margin of 0.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : GYRE
The strongest argument for GYRE centers on Revenue Growth. Revenue growth of 33.4% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : GYRE
The primary concerns for GYRE are EPS Growth, Market Cap, Profit Margin. A P/E of 336.0x leaves little room for execution misses. Thin 4.3% margins leave little buffer for downturns.
Key Dynamics to Monitor
GYRE carries more volatility with a beta of 6.92 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ALNY scores higher overall (49/100 vs 39/100) and 84.9% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Gyre Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Gyre Therapeutics Inc. is a biopharmaceutical innovator focused on developing groundbreaking therapies for rare and complex diseases. Leveraging a proprietary platform, the company accelerates the discovery and commercialization of precision treatments tailored to address significant unmet medical needs. With a strong commitment to scientific rigor and patient-centered outcomes, Gyre is strategically positioned to advance its pipeline in gene therapy and precision medicine. Their dedication to research excellence and strategic partnerships highlights their potential for substantial growth in an increasingly competitive biopharmaceutical sector.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?